vimarsana.com

Page 7 - பென் பெரல்மேன் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Five years later: CAR T therapy shows long-lasting remissions in non-Hodgkin lymphomas

Five years later: CAR T therapy shows long-lasting remissions in non-Hodgkin lymphomas Findings represent the longest follow-up data to date for a personalized cellular therapy approved by the FDA for the treatment of aggressive lymphomas. A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported in the Medicine. The findings represent the longest follow-up, published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory large B-cell lymphomas.

Can vaccinated people still spread COVID-19? How long does immunity last? Here s what science knows now

CHOP doctors study COVID impact on preterm birth disparities by race

WHYY By (Tembinkosi Sikupela / Unsplash) Heather Burris remembers growing up in a small, predominantly Black suburb on the north end of Hartford, Connecticut. Burris would go on to pursue a career in medicine, but she said her early experiences as a white girl in her hometown had an immense impact on her life’s trajectory. “Within my small micro-community, I was a minority and was able to see the world in more of a racialized lens,” said Dr. Burris. “And so when I came into medicine [and] I would see the sort of over-representation of Black infants in the neonatal intensive care unit, I started asking questions why.”

RNA vaccines have never been manufactured before, so making millions of doses was bound to take time Here s how it s done

RNA vaccines have never been manufactured before, so making millions of doses was bound to take time. Here’s how it’s done. Tom Avril, The Philadelphia Inquirer © DAVID MAIALETTI/The Philadelphia Inquirer/TNS Katalin Kariko, senior vice president at BioNTech. Kariko s research on RNA years ago (at Penn) was instrumental in the development of two of the COVID RNA vaccines. A few short months ago, there was a fair amount of public skepticism that RNA vaccines would work against COVID-19, given that no such drug had been approved for preventing any other disease. Now that the injections have been shown to offer near-total protection, millions want to know why they can’t have one immediately.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.